EFFECTS OF CHROMOSOME DUPLICATIONS - Bar phenotype in Drosophila

TLS Online TPP Program

#Id: 3976

#Unit 2. Cellular Organization

A bacterial type II enzyme, called either topoisomerase II or DNA gyrase, can introduce negative supercoils (decrease Lk). It uses the energy of ATP to accomplish this.

To alter DNA linking number, type II topoisomerases cleave both strands of a DNA molecule and pass another duplex through the break.

TLS Online TPP Program

#Id: 3977

#Unit 2. Cellular Organization

The degree of supercoiling of bacterial DNA is maintained by regulation of the net activity of topoisomerases, I and II.

TLS Online TPP Program

#Id: 3980

#Unit 2. Cellular Organization

Eukaryotic cells also have type I and type II topoisomerases. The type I enzymes are topoisomerases I and III;

The eukaryotic type II topoisomerases cannot underwind DNA (introduce negative supercoils), but they can relax both positive and negative supercoils.

TLS Online TPP Program

#Id: 3981

#Unit 2. Cellular Organization

The quinolone antibiotics, inhibits bacterial DNA gyrase and topoisomerase IV, as ciprofloxacin (Cipro). The quinolones act by blocking the last step of the topoisomerase reaction, the resealing of the DNA strand breaks. Ciprofloxacin is a wide-spectrum antibiotic.

TLS Online TPP Program

#Id: 3982

#Unit 2. Cellular Organization

Camptothecin is an inhibitor of eukaryotic type I topoisomerases.

Irinotecan (Campto) and topotecan (Hycamtin)—used to treat colorectal cancer and ovarian cancer.

All these drug's act by trapping the topoisomerase-DNA complex in which the DNA is cleaved, inhibiting religation.

TLS Online TPP Program

#Id: 3983

#Unit 2. Cellular Organization

The human type II topoisomerases are targeted by doxorubicin (Adriamycin), etoposide (Etopophos), and ellipticine.

Most of these drugs stabilize the covalent topoisomerase-DNA (cleaved) complex.